BioPharmSignal logoBioPharmSignal

Biotech News

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Personalis (PSNL)PersonalisEarnings

Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for

Related news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

LEGNLegend Biotech Corporation2026-08-11 11:00 EST

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

View all latest news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

PSNLPersonalis2026-07-20 12:30 EST

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

PSNLPersonalis2026-07-14 10:00 EST

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

PSNLPersonalis2026-06-09 10:00 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-02 10:00 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Stock data

Close
18.38 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States